GILD – gilead sciences, inc. (US:NASDAQ)

DELAYED
$ usd
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
1D
5D
1M
3M
YTD
1Y
3Y
1 Day GILD SPY QQQ SPX
Date
Time
Symbol
Company Name
Action
%Chg
10/30/2025
04:02 pm
gild
gilead sciences, inc.
BEAT
1.5%
8/7/2025
04:02 pm
gild
gilead sciences, inc.
BEAT
8.6%
4/24/2025
04:02 pm
gild
gilead sciences, inc.
BEAT
-2.8%
2/11/2025
04:02 pm
gild
gilead sciences, inc.
BEAT
7.5%
Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions?
The answers are right here.
Stock Stats
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Order Stats
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
Top News Gainers
3/18 Japanese flu drug appears ‘effective’ in coronavirus treatment in Chinese clinical trials [TechCrunch Blog] 9.5%
3/1 2 Stocks That Can Help You Protect Your Wealth From a Coronavirus Pandemic [The Motley Fool] 8.3%
2/25 U.S. Health Officials Start First Clinical Trial With Gilead Sciences' Experimental Coronavirus Treatment [The Motley Fool] 6.6%
3/6 Can Gilead Change Its Dim Fortunes On An Immuno-Oncology Buyout? [Investor's Business Daily] 6.4%
4/2 Gilead in-licenses multiple CAR antibodies from TeneoBio [Seeking Alpha] 6.2%
4/29 Gilead's remdesivir meets main goal of trial in COVID-19 patients [Reuters] 5.5%
1/31 UPDATE 2-Gilead working with China to test Ebola drug as new coronavirus treatment [Reuters] 5.0%
3/10 Gilead Presents 96-week DISCOVER Trial Data Demonstrating Favorable Renal and Bone Safety Profile of Descovy® for HIV PrEP in At-Risk Populations 4.7%
3/26 Gilead Sciences, Inc. (NASDAQ: GILD) had its "buy" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $83.00 price target on the stock. 4.5%
4/24 European shares slide as EU stimulus fails to impress [Reuters] 3.8%
Top News Decliners
3/20 Gilead Sciences, Inc. (NASDAQ: GILD) was upgraded by analysts at Piper Sandler from a "neutral" rating to an "overweight" rating. They now have a $90.00 price target on the stock, up previously from $70.00. -9.3%
2/27 Gilead Sciences, Inc. (NASDAQ: GILD) is now covered by analysts at Barclays PLC. They set an "underweight" rating on the stock. -9.1%
3/6 Gilead Surges To 2-Year High On Expectations For Speedy Coronavirus Drug [Investor's Business Daily] -8.4%
2/3 Gilead +12% on coronavirus treatment testing [Seeking Alpha] -7.3%
3/11 The index dropped at least 20% from its recent peak as coronavirus continues to whiplash investors [CNN] -6.6%
2/25 U.S. Stock-Index Futures Advance on Dip-Buying After Rout [Yahoo! Finance News] -6.4%
2/27 Gilead Sciences makes takeover approach to Forty Seven: Bloomberg News [Reuters] -6.3%
4/16 Gilead surges after report suggests COVID-19 patients responding to remdesivir [Reuters] -5.8%
3/24 Form DEF 14A GILEAD SCIENCES INC For: May 06 -5.6%
4/20 Dow futures fall more than 150 points as US crude prices plunge [CNBC] -5.0%

Don’t Miss Out On The Next BIG Stock Move

Thanks for submitting the form.
GILD – gilead sciences, inc. (US:NASDAQ)
DELAYED
$ usd
1D
5D
1M
3M
YTD
1Y
3Y
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
GILD
SPY
QQQ
SPX
GILD – gilead sciences, inc. (US:NASDAQ)
DELAYED
$ usd
1D
5D
1M
3M
YTD
1Y
3Y
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
GILD SPY QQQ SPX
Stock Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
Stock Stats
Order Stats
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
News
12/12
09:21 am
gild
Low
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Morgan Stanley from $147.00 to $151.00. They now have an "overweight" rating on the stock.
12/10
11:33 am
gild
Low
Cantor Fitzgerald Maintains a Buy Rating on Gilead Sciences (GILD) [Yahoo! Finance]
12/10
09:21 am
gild
Low
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at HSBC Holdings plc from $110.00 to $133.00. They now have a "hold" rating on the stock.
12/10
09:21 am
gild
Low
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Wells Fargo & Company from $145.00 to $150.00. They now have an "overweight" rating on the stock.
12/9
08:30 am
gild
Low
Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer
12/9
08:11 am
gild
Low
Gilead Sciences (NASDAQ:GILD) was upgraded by analysts at UBS Group AG to a "hold" rating.
12/7
08:00 am
gild
Low
Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025
12/7
03:37 am
gild
Low
Why The Narrative Around Gilead Sciences Is Shifting After HIV And Oncology Updates [Yahoo! Finance]
12/6
02:00 pm
gild
Low
Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple Myeloma
10/30/2025
04:02 pm
gild
1.5%
BEAT
8/7/2025
04:02 pm
gild
8.6%
BEAT
4/24/2025
04:02 pm
gild
-2.8%
BEAT
2/11/2025
04:02 pm
gild
7.5%
BEAT
Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions? The answers are right here.
12/12
12:07 pm
Maintains
Overweight
Overweight
Morgan Stanley
Low
-1.4%
12/12
12:07 pm
Maintains
Overweight
Overweight
Morgan Stanley
Low
-1.4%
12/10
03:04 pm
Maintains
Overweight
Overweight
Wells Fargo
Low
0.3%
12/10
03:04 pm
Maintains
Overweight
Overweight
Wells Fargo
Low
0.3%
12/9
08:11 am
Upgrades
Hold
UBS Group AG
Low
-1.5%
11/14
07:52 am
Upgrades
Strong-Buy
Scotiabank
Low
-1.4%
11/14
07:52 am
Upgrades
Strong-Buy
Scotiabank
Low
-1.4%
11/13
01:10 pm
Maintains
Buy
Buy
Needham
Low
-0.8%
11/13
01:10 pm
Maintains
Buy
Buy
Needham
Low
-0.8%
12/11
08:40 pm
gild
Low
Form 4 GILEAD SCIENCES, INC. For: Dec 10 Filed by: Dickinson Andrew D
12/11
08:39 pm
gild
Low
Form 4 GILEAD SCIENCES, INC. For: Dec 10 Filed by: O'Day Daniel Patrick
12/11
06:26 pm
gild
Low
Form 4 GILEAD SCIENCES, INC. For: Dec 10 Filed by: Mercier Johanna
12/1
06:12 pm
gild
Low
Form 4 GILEAD SCIENCES, INC. For: Nov 28 Filed by: Bluestone Jeffrey
12/1
04:55 pm
gild
Medium
Form 4 GILEAD SCIENCES, INC. For: Nov 26 Filed by: Kramer Kelly A.
12/1
04:51 pm
gild
Low
Form 4 GILEAD SCIENCES, INC. For: Nov 28 Filed by: O'Day Daniel Patrick
11/28
01:06 pm
gild
Neutral
Form 144 GILEAD SCIENCES, INC. Filed by: O'Day Daniel Patrick
11/28
01:03 pm
gild
Neutral
Form 144 GILEAD SCIENCES, INC. Filed by: Bluestone Jeffrey
11/26
04:16 pm
gild
Low
Form 144 GILEAD SCIENCES, INC. Filed by: Kramer Kelly A.
Show more
Top News Gainers
3/18 Japanese flu drug appears ‘effective’ in coronavirus treatment in Chinese clinical trials [TechCrunch Blog] 9.5%
3/1 2 Stocks That Can Help You Protect Your Wealth From a Coronavirus Pandemic [The Motley Fool] 8.3%
2/25 U.S. Health Officials Start First Clinical Trial With Gilead Sciences' Experimental Coronavirus Treatment [The Motley Fool] 6.6%
3/6 Can Gilead Change Its Dim Fortunes On An Immuno-Oncology Buyout? [Investor's Business Daily] 6.4%
4/2 Gilead in-licenses multiple CAR antibodies from TeneoBio [Seeking Alpha] 6.2%
4/29 Gilead's remdesivir meets main goal of trial in COVID-19 patients [Reuters] 5.5%
1/31 UPDATE 2-Gilead working with China to test Ebola drug as new coronavirus treatment [Reuters] 5.0%
3/10 Gilead Presents 96-week DISCOVER Trial Data Demonstrating Favorable Renal and Bone Safety Profile of Descovy® for HIV PrEP in At-Risk Populations 4.7%
3/26 Gilead Sciences, Inc. (NASDAQ: GILD) had its "buy" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $83.00 price target on the stock. 4.5%
4/24 European shares slide as EU stimulus fails to impress [Reuters] 3.8%
Top News Decliners
3/20 Gilead Sciences, Inc. (NASDAQ: GILD) was upgraded by analysts at Piper Sandler from a "neutral" rating to an "overweight" rating. They now have a $90.00 price target on the stock, up previously from $70.00. -9.3%
2/27 Gilead Sciences, Inc. (NASDAQ: GILD) is now covered by analysts at Barclays PLC. They set an "underweight" rating on the stock. -9.1%
3/6 Gilead Surges To 2-Year High On Expectations For Speedy Coronavirus Drug [Investor's Business Daily] -8.4%
2/3 Gilead +12% on coronavirus treatment testing [Seeking Alpha] -7.3%
3/11 The index dropped at least 20% from its recent peak as coronavirus continues to whiplash investors [CNN] -6.6%
2/25 U.S. Stock-Index Futures Advance on Dip-Buying After Rout [Yahoo! Finance News] -6.4%
2/27 Gilead Sciences makes takeover approach to Forty Seven: Bloomberg News [Reuters] -6.3%
4/16 Gilead surges after report suggests COVID-19 patients responding to remdesivir [Reuters] -5.8%
3/24 Form DEF 14A GILEAD SCIENCES INC For: May 06 -5.6%
4/20 Dow futures fall more than 150 points as US crude prices plunge [CNBC] -5.0%